Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease

Qasim Akram; Mark Roberts; Chester Oddis; Ariane Herrick; Hector Chinoy

doi:10.5114/reum.2016.58760

Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease

Qasim Akram, Mark Roberts, Chester Oddis, Ariane Herrick, Hector Chinoy

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, it has never been described in a patient with myositis and systemic sclerosis overlap disease. We describe a case of LON in a 54-year-old man who was diagnosed with myositis and then systemic sclerosis overlap disease. It resolved within 7 days, and the patient did not suffer neutropenic sepsis or any other complications. We propose similar mechanisms for LON as described in other conditions and routine blood monitoring in such patients.

Original language	English
Pages (from-to)	35-37
Number of pages	3
Journal	Reumatologia Clinica
Volume	54
Issue number	1
DOIs	https://doi.org/10.5114/reum.2016.58760
Publication status	Published - 24 Mar 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5114/reum.2016.58760Licence: CC BY-NC-SA

Cite this

@article{8520372e5e5e49e1bbfc5e24526cb3ac,

title = "Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease",

abstract = "Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, it has never been described in a patient with myositis and systemic sclerosis overlap disease. We describe a case of LON in a 54-year-old man who was diagnosed with myositis and then systemic sclerosis overlap disease. It resolved within 7 days, and the patient did not suffer neutropenic sepsis or any other complications. We propose similar mechanisms for LON as described in other conditions and routine blood monitoring in such patients.",

author = "Qasim Akram and Mark Roberts and Chester Oddis and Ariane Herrick and Hector Chinoy",

year = "2016",

month = mar,

day = "24",

doi = "10.5114/reum.2016.58760",

language = "English",

volume = "54",

pages = "35--37",

journal = "Reumatologia Clinica",

issn = "0034-6233",

publisher = "Termedia Publishing House",

number = "1",

}

TY - JOUR

T1 - Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease

AU - Akram, Qasim

AU - Roberts, Mark

AU - Oddis, Chester

AU - Herrick, Ariane

AU - Chinoy, Hector

PY - 2016/3/24

Y1 - 2016/3/24

N2 - Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, it has never been described in a patient with myositis and systemic sclerosis overlap disease. We describe a case of LON in a 54-year-old man who was diagnosed with myositis and then systemic sclerosis overlap disease. It resolved within 7 days, and the patient did not suffer neutropenic sepsis or any other complications. We propose similar mechanisms for LON as described in other conditions and routine blood monitoring in such patients.

AB - Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, it has never been described in a patient with myositis and systemic sclerosis overlap disease. We describe a case of LON in a 54-year-old man who was diagnosed with myositis and then systemic sclerosis overlap disease. It resolved within 7 days, and the patient did not suffer neutropenic sepsis or any other complications. We propose similar mechanisms for LON as described in other conditions and routine blood monitoring in such patients.

U2 - 10.5114/reum.2016.58760

DO - 10.5114/reum.2016.58760

M3 - Article

C2 - 27407275

SN - 0034-6233

VL - 54

SP - 35

EP - 37

JO - Reumatologia Clinica

JF - Reumatologia Clinica

IS - 1

ER -

Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this